146 related articles for article (PubMed ID: 32995264)
1. Alkalescent soda beverage caused the disappearance of gefitinib-induced rashes and decreased efficacy in a non-small-cell lung cancer patient treated with gefitinib: A case report.
Bian S; Tang X; Ye S; Lei W
Respir Med Case Rep; 2020; 31():101228. PubMed ID: 32995264
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy and safety of gefitinib monotherapy for Chinese elderly patients with advanced non-small cell lung cancer].
Zhang L; Wang SL; Zhang XT; Li LY; Wang MZ
Zhonghua Nei Ke Za Zhi; 2007 May; 46(5):392-5. PubMed ID: 17637309
[TBL] [Abstract][Full Text] [Related]
3. Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line chemotherapy regardless of epidermal growth factor receptor mutation: a review in Chinese patients.
Biaoxue R; Shuanying Y; Wei L; Wei Z; Zongjuan M
Curr Med Res Opin; 2012 Oct; 28(10):1699-708. PubMed ID: 22978775
[TBL] [Abstract][Full Text] [Related]
4. Rechallenge with gefitinib following severe drug-induced hepatotoxicity in a patient with advanced non-small cell lung cancer: A case report and literature review.
Chen X; Pan Y; Zhang S; Chen D; Yang S; Li X; Ma S
Oncol Lett; 2014 Mar; 7(3):878-880. PubMed ID: 24527096
[TBL] [Abstract][Full Text] [Related]
5. Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer: A case report and review of the literature.
Ferrazzi A; Russo I; Pasello G; Alaibac M
Exp Ther Med; 2016 Jan; 11(1):197-200. PubMed ID: 26889239
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.
Fang H; Lin RY; Sun MX; Wang Q; Zhao YL; Yu JL; Tian Y; Wang XY
Asian Pac J Cancer Prev; 2014; 15(24):10967-70. PubMed ID: 25605210
[TBL] [Abstract][Full Text] [Related]
7. Hemorrhage of brain metastasis from non-small cell lung cancer post gefitinib therapy: two case reports and review of the literature.
Yan DF; Yan SX; Yang JS; Wang YX; Sun XL; Liao XB; Liu JQ
BMC Cancer; 2010 Feb; 10():49. PubMed ID: 20170543
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib induced severe hyponatremia: A case report.
Meena DS; Kumar D; Bohra GK; Midha N
J Oncol Pharm Pract; 2021 Apr; 27(3):711-715. PubMed ID: 32686614
[TBL] [Abstract][Full Text] [Related]
9. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets.
Cohen MH; Williams GA; Sridhara R; Chen G; McGuinn WD; Morse D; Abraham S; Rahman A; Liang C; Lostritto R; Baird A; Pazdur R
Clin Cancer Res; 2004 Feb; 10(4):1212-8. PubMed ID: 14977817
[TBL] [Abstract][Full Text] [Related]
10. Long-term progression-free survival in a patient with advanced non-small-cell lung cancer treated with low-dose gefitinib and traditional herbal medicine: A case report.
Lee BJ; Kim KI; Choi CW; Kim JY; Lee JH
Medicine (Baltimore); 2021 Feb; 100(5):e24292. PubMed ID: 33592873
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of efficacy and safety of ZD1839 as monotherapy in Chinese patients with advanced non-small cell lung cancer].
Wang MZ; Li LY; Wang SL; Zhang XT; Zhong W; Zhang L; Li JR
Zhonghua Nei Ke Za Zhi; 2008 Apr; 47(4):291-5. PubMed ID: 18843952
[TBL] [Abstract][Full Text] [Related]
12. The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib.
Grossi F; Rijavec E; Dal Bello MG; Defferrari C; Brianti A; Barletta G; Genova C; Murolo C; Cosso M; Fontanini G; Boldrini L; Truini M; Pronzato P
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1407-12. PubMed ID: 22349923
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of efficacy and safety of gefitinib as monotherapy in Chinese patients with advanced non-small cell lung cancer and very poor performance status.
Wei Z; Mengzhao W; Li Z; Longyun L; Xiaotong Z
BMC Res Notes; 2008 Oct; 1():102. PubMed ID: 18957121
[TBL] [Abstract][Full Text] [Related]
14. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study.
Hu WX; Peng JC; Wang Y; Jin H; Geng N
Int J Gen Med; 2022; 15():4453-4464. PubMed ID: 35509604
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib-induced hemorrhagic cystitis and inflammatory contracted bladder in a patient with advanced lung adenocarcinoma harboring compound epidermal growth factor receptor G719S and S768I missense mutations: a case report.
Bai X; Cheng J; Zhao L; Cheng M
Ann Transl Med; 2022 Jul; 10(14):809. PubMed ID: 35965829
[TBL] [Abstract][Full Text] [Related]
17. First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.
Kuwako T; Imai H; Masuda T; Miura Y; Seki K; Yoshino R; Kaira K; Utsugi M; Shimizu K; Sunaga N; Tomizawa Y; Ishihara S; Ishizuka T; Mogi A; Hisada T; Minato K; Takise A; Saito R; Yamada M
Cancer Chemother Pharmacol; 2015 Oct; 76(4):761-9. PubMed ID: 26254024
[TBL] [Abstract][Full Text] [Related]
18. A severe dermatologic adverse effect related with gefitinib: case report and review of the literature.
Li YQ; Sun H; Xue D
J Cancer Res Ther; 2013 Sep; 9 Suppl 2():S110-3. PubMed ID: 24135241
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
Mu XL; Li LY; Zhang XT; Wang SL; Wang MZ
BMC Cancer; 2004 Aug; 4():51. PubMed ID: 15318946
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
